 |  |
Autoimmune drug by Bristol Myers shows potential in lupus
Deucravacitinib is one of nine new drugs that Bristol Myers executives believe will help offset revenue losses
Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar | 623
PerkinElmer unveils ultrarapid whole-genome sequencing
The urWGS offering provides physicians with comprehensive, meaningful results in five days to help inform clinical management and improve outcomes
Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar | 456
BioNTech 2nd phase of Covid 19 trials completed
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine
Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar | 480
US FDA approval for Incyte's Olumiant
Eli Lilly and Company and Incyte announced the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of Covid-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days.
Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar | 533
The Dutch company MIMETAS expanded its license to the HUB Organoid Technology to include all organs
These miniature organs are used to develop therapies against incurable diseases.
Drug Discovery & Development | 11/05/2022 | By Content editor | 890
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy